Literature DB >> 28705859

Checking up on checkpoint inhibitors.

Richard F Little1, Howard Streicher1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28705859      PMCID： PMC5510793          DOI： 10.1182/blood-2017-05-783696

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  6 in total

Review 1.  Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis.

Authors:  A Rashidi; M Ebadi; A F Cashen
Journal:  Bone Marrow Transplant       Date:  2016-01-04       Impact factor: 5.483

2.  Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

Authors:  Matthew S Davids; Haesook T Kim; Pavan Bachireddy; Caitlin Costello; Rebecca Liguori; Alexandra Savell; Alexander P Lukez; David Avigan; Yi-Bin Chen; Peter McSweeney; Nicole R LeBoeuf; Michael S Rooney; Michaela Bowden; Chensheng W Zhou; Scott R Granter; Jason L Hornick; Scott J Rodig; Masahiro Hirakawa; Mariano Severgnini; F Stephen Hodi; Catherine J Wu; Vincent T Ho; Corey Cutler; John Koreth; Edwin P Alyea; Joseph H Antin; Philippe Armand; Howard Streicher; Edward D Ball; Jerome Ritz; Asad Bashey; Robert J Soiffer
Journal:  N Engl J Med       Date:  2016-07-14       Impact factor: 91.245

3.  Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.

Authors:  Charles Herbaux; Jordan Gauthier; Pauline Brice; Elodie Drumez; Loic Ysebaert; Hélène Doyen; Luc Fornecker; Krimo Bouabdallah; Guillaume Manson; Hervé Ghesquières; Reza Tabrizi; Eric Hermet; Julien Lazarovici; Anne Thiebaut-Bertrand; Adrien Chauchet; Hélène Demarquette; Eileen Boyle; Roch Houot; Ibrahim Yakoub-Agha; Franck Morschhauser
Journal:  Blood       Date:  2017-03-07       Impact factor: 22.113

4.  PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.

Authors:  Bradley M Haverkos; Diana Abbott; Mehdi Hamadani; Philippe Armand; Mary E Flowers; Reid Merryman; Manali Kamdar; Abraham Sebastian Kanate; Ayman Saad; Amitkumar Mehta; Siddhartha Ganguly; Timothy S Fenske; Parameswaran Hari; Robert Lowsky; Leslie Andritsos; Madan Jagasia; Asad Bashey; Stacey Brown; Veronika Bachanova; Deborah Stephens; Shin Mineishi; Ryotaro Nakamura; Yi-Bin Chen; Bruce R Blazar; Jonathan Gutman; Steven M Devine
Journal:  Blood       Date:  2017-05-03       Impact factor: 22.113

5.  PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells.

Authors:  Xiong Ni; Qingxiao Song; Kaniel Cassady; Ruishu Deng; Hua Jin; Mingfeng Zhang; Haidong Dong; Stephen Forman; Paul J Martin; Yuan-Zhong Chen; Jianmin Wang; Defu Zeng
Journal:  J Clin Invest       Date:  2017-04-17       Impact factor: 14.808

6.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245
  6 in total
  1 in total

Review 1.  Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80.

Authors:  Kaniel Cassady; Paul J Martin; Defu Zeng
Journal:  Front Immunol       Date:  2018-12-21       Impact factor: 7.561
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.